Humana (NYSE:HUM) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday, ValuEngine reports.

Several other equities research analysts also recently weighed in on HUM. Canaccord Genuity reaffirmed a “buy” rating on shares of Humana in a report on Monday, October 21st. SunTrust Banks raised their target price on Humana to $335.00 and gave the company a “hold” rating in a report on Thursday. They noted that the move was a valuation call. Mizuho initiated coverage on Humana in a report on Thursday, October 17th. They issued a “buy” rating and a $316.00 target price for the company. UBS Group raised their target price on Humana from $266.00 to $317.00 and gave the company a “neutral” rating in a report on Thursday, August 1st. Finally, Berenberg Bank reissued a “buy” rating on shares of Humana in a report on Monday, October 21st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and fourteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $322.63.

Shares of NYSE HUM traded up $2.44 during mid-day trading on Friday, hitting $317.58. 1,173,375 shares of the company were exchanged, compared to its average volume of 1,220,728. The company has a quick ratio of 1.75, a current ratio of 1.75 and a debt-to-equity ratio of 0.37. The stock has a 50 day simple moving average of $277.48 and a 200-day simple moving average of $270.93. Humana has a 1-year low of $225.65 and a 1-year high of $342.03. The firm has a market cap of $39.82 billion, a price-to-earnings ratio of 21.83, a price-to-earnings-growth ratio of 1.27 and a beta of 0.85.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, November 6th. The insurance provider reported $5.03 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $4.58 by $0.45. Humana had a return on equity of 22.47% and a net margin of 4.13%. The firm had revenue of $16.24 billion during the quarter, compared to the consensus estimate of $16.15 billion. During the same period last year, the company earned $4.58 earnings per share. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. Analysts anticipate that Humana will post 17.75 earnings per share for the current fiscal year.

In other news, insider Brian P. Leclaire sold 7,239 shares of the firm’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $289.70, for a total value of $2,097,138.30. Following the completion of the transaction, the insider now owns 12,994 shares in the company, valued at $3,764,361.80. The sale was disclosed in a document filed with the SEC, which is available at this link. 0.54% of the stock is currently owned by company insiders.

Several hedge funds have recently made changes to their positions in HUM. Endurance Wealth Management Inc. increased its position in shares of Humana by 354.5% in the third quarter. Endurance Wealth Management Inc. now owns 100 shares of the insurance provider’s stock valued at $26,000 after buying an additional 78 shares in the last quarter. Whittier Trust Co. purchased a new position in shares of Humana in the second quarter valued at $27,000. Next Capital Management LLC purchased a new position in shares of Humana in the second quarter valued at $27,000. Quest Capital Management Inc. ADV purchased a new position in shares of Humana in the third quarter valued at $30,000. Finally, Advantage Investment Management LLC increased its position in shares of Humana by 287.1% in the second quarter. Advantage Investment Management LLC now owns 120 shares of the insurance provider’s stock valued at $32,000 after buying an additional 89 shares in the last quarter. Institutional investors and hedge funds own 92.93% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

See Also: 52-week highs

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.